2 / 12
Page 15
Notes:
allied
academies
J Med Oncl Ther 2017 | Volume 2 Issue 3
Breast Cancer
November 01-02, 2017 | Toronto, Canada
7
th
World Congress on
Novel therapeutic drug combinations with CDK4/6 inhibitors, beyond ER+ve breast cancer
Uzma Saddia Asghar
1,2
1
University College London Hospital, UK
2
Institute of Cancer Research, London
T
he CDK4/6 – RB1 axis controls transition through the
restriction point in the G1 phase of the cell cycle, and
cancers frequently subvert the regulation of this axis
to promote proliferation. CDK4/6 inhibition is a proven
therapeutic strategy for estrogen receptor positive (ER+ve)
breast cancers, with selective CDK4/6 inhibitors (palbociclib
and ribociclib) demonstrating substantial improvements in
progression free survival in phase two and three clinical trials
(PALOMA1, PALOMA2, PALOMA3 and MONALEESA-2). There
is considerable interest in exploring the role CDK4/6 inhibitors
in drug combinations for patients with HER2 amplified breast
groups and the TNBC subtypes. Triple negative breast cancer
(TNBC) is an aggressive subtype of breast cancer associated
with poor prognosis. Although TNBC may be sensitive to
chemotherapy there is a substantial need to identify novel
targeted therapeutic strategies. TNBC are a heterogeneous
group of tumours with gene expression profiling identifying
distinct subgroups, including luminal androgen receptor
(LAR), mesenchymal stem like (MSL), mesenchymal (MES),
and basal-like.
In vitro
data and
in vivo
data have shown that
the LAR subtypes of breast cancer are highly sensitive to
CDK4/6 inhibition and this is currently being tested in clinical
trials. There is now growing amount of data suggesting that
CDK4/6 inhibitor drug combinations, may have a role in
breast cancer subtypes, beyond ER receptor positivity.
Speaker Biography
Uzma Saddia Asghar was awarded her MBBS (2004) and intercalated BSc in
Neurosciences (2001) from University College London (UCL). She was awarded her
MRCP in 2008 (London) and did her PhD at Breast Cancer now, Institute of Cancer,
London as an Avon Clinical Research Fellow (2017). Her interests includes novel
targeted therapeutic agents for breast cancer, inhibitors of cell cycle and PI3 kinase
signaling pathway, immunotherapy and drug development and currently setting up
these breast translational clinical trials at UCL.
e:
uzmaasg@yahoo.co.uk